FIELD: medicine.
SUBSTANCE: compositions for the treatment of Alzheimer’s disease are proposed, containing at least one AAV vector. A method for the treatment of Alzheimer’s disease is proposed, including the intrathecal delivery to a patient of one of the above-mentioned compositions, in which biomass of at least one vector expresses immunoglobulin, specific to Aβ, beta-secretase and/or tau protein.
EFFECT: proposed group of inventions provides for the effective treatment of Alzheimer’s disease.
11 cl, 1 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION AND METHOD FOR TREATING A COMPLEMENT-MEDIATED DISEASE | 2016 |
|
RU2727411C2 |
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| EXPRESSION OF ANTIGEN-BINDING PROTEINS IN NERVOUS SYSTEM | 2020 |
|
RU2831086C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| METHODS FOR TREATMENT OF DANON'S DISEASE AND OTHER AUTOPHAGY DISORDERS | 2017 |
|
RU2777571C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES, AND THEIR APPLICATION | 2017 |
|
RU2764919C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
